Abstract: A hydraulic regenerative braking system is provided for using hydraulic fluid to capture energy from a vehicle during a braking event. The system captures kinetic energy from a shaft of the vehicle and stores the kinetic energy as hydraulic potential energy. That is, the system captures rotational energy as hydraulic potential energy in an accumulator. The hydraulic regenerative braking system also discharges the hydraulic potential energy as kinetic energy. During braking, kinetic energy is transferred from the vehicle shaft to a gearbox, and from the gearbox to a hydraulic pump. The hydraulic pump uses the kinetic energy to pump hydraulic fluid to an accumulator, increasing the hydraulic potential energy stored in the accumulator. During driving, the hydraulic fluid is released from the accumulator to the hydraulic pump, generating kinetic energy that is transferred to the vehicle shaft via the gearbox.

Abstract: A hydraulic regenerative braking system is provided for using hydraulic fluid to capture energy from a vehicle during a braking event. The system captures kinetic energy from a shaft of the vehicle and stores the kinetic energy as hydraulic potential energy. That is, the system captures rotational energy as hydraulic potential energy in an accumulator. The hydraulic regenerative braking system also discharges the hydraulic potential energy as kinetic energy. During braking, kinetic energy is transferred from the vehicle shaft to a gearbox, and from the gearbox to a hydraulic pump. The hydraulic pump uses the kinetic energy to pump hydraulic fluid to an accumulator, increasing the hydraulic potential energy stored in the accumulator. During driving, the hydraulic fluid is released from the accumulator to the hydraulic pump, generating kinetic energy that is transferred to the vehicle shaft via the gearbox.

Abstract: A hydraulic hybrid system for implementation in a machine. The system includes a hydraulic system, an energy source, an output, and a transmission. The hydraulic system includes a primary hydraulic pump/motor (primary motor) that is hydraulically coupled to a reservoir and a variable-volume accumulator assembly. The primary motor is configured to charge an accumulator of the variable-volume accumulator assembly with a working fluid when mechanically driven. The storage volume of variable-volume accumulator assembly varies based on a kinetic output condition of the machine. The energy source is configured to produce primary kinetic energy. The output is configured to receive at least a first portion of the primary kinetic energy. The transmission is coupled between the energy source and the output and selectively coupled to the primary motor. The transmission is configured to mechanically drive the primary motor using a second portion of the primary kinetic energy.

Abstract: An example embodiment includes a hydraulic hybrid system. The hydraulic hybrid system includes a hydraulic system, an energy source configured to produce primary kinetic energy, an output configured to receive at least a first portion of the primary kinetic energy, and a transmission coupled between the energy source and the output and selectively coupled to the hydraulic system. The hydraulic system includes a reservoir, a sequenced accumulator assembly, and a hydraulic pump/motor that is hydraulically coupled to the reservoir and the sequenced accumulator assembly and configured to charge the sequenced accumulator assembly when mechanically driven. The sequenced accumulator assembly includes two or more accumulators, one or more sequence valves, and one or more check valves. The sequenced accumulator assembly is configured to store varying amounts of potential hydraulic energy by introducing and removing one or more of the accumulators from operation.

Abstract: A hydraulic hybrid system for implementation in a machine. The system includes a hydraulic system, an energy source, an output, and a transmission. The hydraulic system includes a primary hydraulic pump/motor (primary motor) that is hydraulically coupled to a reservoir and a variable-volume accumulator assembly. The primary motor is configured to charge an accumulator of the variable-volume accumulator assembly with a working fluid when mechanically driven. The storage volume of variable-volume accumulator assembly varies based on a kinetic output condition of the machine. The energy source is configured to produce primary kinetic energy. The output is configured to receive at least a first portion of the primary kinetic energy. The transmission is coupled between the energy source and the output and selectively coupled to the primary motor. The transmission is configured to mechanically drive the primary motor using a second portion of the primary kinetic energy.

Abstract: Film structures, packages, films and methods of making the same are provided wherein the film structures have a desiccant material incorporated into at least one layer of the film structures and further wherein the film structures can comprise a material for making a peelable seal when the film structures are heat sealed to other film structures. The film structures are utilized for a package to hold a product that may be sensitive to the presence of moisture. The product may preferably be pharmaceutical products, nutraceutical products, or devices such as absorbable sutures or medical stents, although any moisture-sensitive product is contemplated by the present invention.

Abstract: Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Abstract: A probucol or a probucol derivative can be efficiently converted to a monoester or monoether of probucol by reacting the free hydroxyl-containing probucol or a derivative thereof (by which is meant a probucol compound with at least one substituent that is different from that on the parent probucol molecule but which maintains the two free hydroxyl groups) with a Grignard reagent or a lithium reagent that produces a magnesium bromide or lithium salt of probucol or the probucol derivative. The probucol compound anion anion is then reacted with an ester or ether forming compound.

Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.

Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.

Abstract: Film structures, packages, films and methods of making the same are provided wherein the film structures have a desiccant material incorporated into at least one layer of the film structures and further wherein the film structures can comprise a material for making a peelable seal when the film structures are heat sealed to other film structures. The film structures are utilized for a package to hold a product that may be sensitive to the presence of moisture. The product may preferably be pharmaceutical products, nutraceutical products, or devices such as absorbable sutures or medical stents, although any moisture-sensitive product is contemplated by the present invention.

Abstract: The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

Abstract: Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human inmmunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Abstract: Selected heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Abstract: Selected sulfonylalkanoylamino hydroxyethylamine sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Abstract: It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.

Abstract: Bis-sulfonamido hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease inhibiting compounds of the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the variables are as defined herein.

Abstract: Selected amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Abstract: The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.